Thymogen: L-Glu-L-Trp immune-deficiency use — US5814611A
Vyacheslav Grigorievich Morozov, Vladimir Khatskelevich Khavinson · 1998 · US5814611A · patent family 27555548
Published 1998-09-29.
Reported patent results
Reported findings
The disclosure reports improved inflammatory/wound outcomes and immunological measures, but broad clinical percentage ranges are incompletely specified.
Thymogen patent description summarizes clinical use and laboratory comparisons with thymus extract; cohort-specific denominators are not given with the pooled clinical ranges.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported clinical response range | 75.3–91.7% improvement or healing across described conditions | No single verified denominator or common endpoint supplied |
| Treatment duration | Reported 20–30% shorter than control care | Condition-specific sample sizes and uncertainty are not established from this summary |
| Reported tolerability | No toxic or allergic reactions reported in described clinical applications | Absence of events in a patent narrative does not establish general safety |
Mixed clinical contexts and incomplete group reporting prevent a pooled efficacy estimate. Laboratory potency comparisons with Thymalin are not clinical superiority estimates.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The US claims concern purified L-Glu-L-Trp in a specified immune-deficiency-related use; the broader family traces earlier Thymogen development.
This alpha-linked L/L peptide differs from gamma-linked or D-amino-acid analogues. The granted method is narrower than all possible immune uses.
- Publication
- US5814611A ↗ · 1998-09-29
- Earliest priority / filing
- 1988-12-14 / 1995-06-07
- Original applicant / assignee
- Cytoven JV
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 27555548 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical for the therapy of immune deficiency conditions
Inventors: Vyacheslav Grigorievich Morozov; Vladimir Khatskelevich Khavinson.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- This alpha-linked L/L peptide differs from gamma-linked or D-amino-acid analogues. The granted method is narrower than all possible immune uses.
- Mixed clinical contexts and incomplete group reporting prevent a pooled efficacy estimate. Laboratory potency comparisons with Thymalin are not clinical superiority estimates.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-27555548. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vyacheslav Grigorievich Morozov, Vladimir Khatskelevich Khavinson. Thymogen: L-Glu-L-Trp immune-deficiency use — US5814611A US5814611A · patent family 27555548 1998.
Molekul research summary: https://molekul.io/research/patent-us5814611a. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry